Publications by authors named "A Voulgari"
Background: This phase 1b study (ClinicalTrials.gov identifier NCT03695380) evaluated regimens combining PARP and MEK inhibition, with or without PD-L1 inhibition, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer (PSROC).
Methods: Patients with PSROC who had received one or two prior treatment lines were treated with 28-day cycles of cobimetinib 60 mg daily (days 1-21) plus niraparib 200 mg daily (days 1-28) with or without atezolizumab 840 mg (days 1 and 15).
Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation-positive advanced melanoma. We report long-term follow-up of coBRIM, with at least 5 years since the last patient was randomized.
Patients And Methods: Eligible patients were randomized 1:1 to receive either oral cobimetinib (60 mg once daily on days 1-21 in each 28-day cycle) or placebo in combination with oral vemurafenib (960 mg twice daily).
Biosensors represent an attractive approach for fast bacteria detection. Here, we present an optical biosensor for the detection of lipopolysaccharide (LPS) and bacteria in drinking water, based on white light reflectance spectroscopy. The sensor chip consisted of a Si die with a thin SiO layer on top that was transformed into a biosensor through the immobilization of LPS.
View Article and Find Full Text PDFBackground: Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAF wild-type advanced melanoma.
Patients And Methods: IMspire170 was an international, randomized, open-label, phase III study.
Article Synopsis
- - Researchers studied the effectiveness and safety of lebrikizumab, an IL-13 antibody, alongside topical corticosteroids (TCS) for treating moderate-to-severe atopic dermatitis (AD).
- - In a phase 2 clinical trial, 209 adult participants were randomly assigned to receive different doses of lebrikizumab or a placebo, with the primary goal of achieving a significant reduction in eczema severity after 12 weeks.
- - Results showed that lebrikizumab 125 mg every 4 weeks led to a notably higher percentage of patients achieving significant improvement (EASI-50) compared to the placebo, and the treatment was generally well tolerated, although long-term effects were not assessed.